- LOGIN
- MemberShip
- 2020-10-24 12:01
Dailypharm Korea will be available without login access until the end of December 2019.
Membership login access would be required from February 2020 to access more news and website services.
Membership login access would be required from February 2020 to access more news and website services.
- Company
- Daewoong promotes the development of injectable hair loss tx
- by Nho, Byung Chul Oct 6, 2020 06:23am
- Daewoong is developing long-lasting hair loss treatments for male in earnest through open innovation that introduces promising external technologies. Daewoong (CEO Seng-Ho Jeon) signed a joint development contract with Inventage lab (CEO Ju Hee Kim), a drug delivery system platform venture company, on the 25th, and is conducting joint re
- Company
- Choline alfoscerate coverage reduction order suspended again
- by Chon, Seung-Hyun Oct 5, 2020 06:20am
- The court has once again approved to halt the administrative order on the cognitive enhancer ‘choline alfoscerate.’ Previously, the court has decided to suspend the order until the final ruling of the litigation, but another litigation case added 30 days to the already-approved order suspension. According to the industry sources on
- Company
- Merged BMS-Celgene to offer ERP after all
- by Eo, Yun-Ho Oct 5, 2020 06:20am
- Initially merged with almost no downsizing, Bristol-Myers Squibb (BMS) and Celgene have ultimately decided to slim down the organization in South Korea. According to the pharmaceutical industry sources, BMS Korea has recently decided to issue the Early Retirement Program (ERP) as a result of acquiring Celgene. The staff reduction wou
- Company
- Ildong is accelerating the development of Lasmiditan
- by Kim, Jin-Gu Sep 29, 2020 06:20am
- Ildong is accelerating the development of a new class of migraine treatment 'Lasmiditan'. A large-scale phase III clinical trial is in progress, close to 300 as a bridged clinical trial, and it is confirmed that the registration of subjects has recently been completed. According to the pharmaceutical industry on the 25th, Ildong recent
- Company
- Korean rare disease drug Hunterase market share surges
- by An, Kyung-Jin Sep 29, 2020 06:20am
- Developed with South Korean-made rare disease treating technology, Hunterase (idursulfase-β) continues to top the market. The treatment’s market share gap with Elaprase (idursulfase) that used to dominate the Hunter syndrome market has tripled as Hunterase maintains market share of over 70 percent. While the treatment is generating signifi
- Company
- Pfizer Korea launches Cresemba in Korea
- by Eo, Yun-Ho Sep 28, 2020 06:20am
- Pfizer Korea launched Cresemba (Isavuconazole), an invasive fungal infection treatment in Korea. Cresemba is an antifungal drug approved for the treatment of invasive aspergillosis in adults over 18 years of age and invasive mucormycosis, which is not suitable for administration of Amphotericin B in adults over 18 years of age, and obtain
- Company
- Targeted therapy Tagrisso back on track expanding coverage
- by Eo, Yun-Ho Sep 25, 2020 06:06am
- A third generation targeted therapy Tagrisso is getting back on its track to seek reimbursement as a first-line treatment for patients with lung cancer. The pharmaceutical industry sources confirmed, AstraZeneca Korea has submitted an application to expand reimbursement on its epidermal growth factor receptor (EGFR) tyrosine kinase inhib
- Company
- Janssen MA Director Lim Kyunghwa promoted to Janssen APAC
- by Eo, Yun-Ho Sep 24, 2020 11:59am
- Market Access (MA) Director Lim Kyunghwa at Janssen Korea is to be promoted to Janssen Asia Pacific. The pharmaceutical industry sources reported, Director Lim would be appointed as a new MA Director at Janssen Asia Pacific from coming October. Temporarily, Lim would be remotely working from South Korea amid COVID-19, but she would be wo
- Company
- Suganon by Dong-A ST, approved for Phase II/III in the US
- by An, Kyung-Jin Sep 24, 2020 06:19am
- Dong-A ST announced on the 22nd that the diabetes treatment 'Suganon' (Evogliptin) has been approved by the US Food and Drug Administration (FDA) for Phase IIb/IIIa clinical trial plan (IND) for aortic heart valve calcification. Suganon is a diabetes treatment based on DPP-4 inhibitor developed by Dong-A ST. In order to use Suganon other
- Company
- Suganon, a new domestic drug that is evolving
- by An, Kyung-Jin Sep 23, 2020 08:06pm
- Suganon (Evogliptin), a diabetes treatment developed by Dong-A ST's proprietary technology, has stepped up its competitiveness. Despite the return of rights, efforts are being made to improve the value of new drugs while seeking new indications. The growth of domestic sales has gained momentum, and it is advancing into overseas markets by co
